In a world where access to healthcare should be a universal right, the persistent disparities in health outcomes starkly remind us that health equity remains an elusive goal. Health equity is defined as the absence of unfair and avoidable differences in health among population groups defined socially, economically, demographically, or geographically. This concept underscores the need to ensure that every individual has a fair opportunity to achieve their highest possible level of health, unimpeded by systemic barriers or socioeconomic disadvantages.[1]
Health Economics and Outcomes Research (HEOR) examines the cost-effectiveness, value, and real-world outcomes of healthcare interventions, enabling data-driven resource allocation. HEOR is pivotal in advancing health equity by analyzing the economic and clinical outcomes of healthcare interventions. HEOR evaluates the value of medical treatments and services, providing data-driven insights that inform decisions about the allocation of healthcare resources. By intertwining health equity with health economics, HEOR helps identify which interventions deliver the most significant benefits across diverse populations, guiding efforts to reduce disparities and improve overall health outcomes.[2]
The COVID-19 pandemic showed how social determinants of health, such as income, occupation, and access to technology, impact health equity. Higher-income individuals often had the advantage of working from home, reducing their exposure to the virus and benefiting from better internet connectivity, which enabled access to virtual healthcare. In contrast, essential workers in lower-paying jobs faced greater exposure and limited healthcare access, leading to worse outcomes. These disparities highlight the urgent need to reevaluate healthcare practices and structures to address inequities effectively.[3-5]
HEOR plays a critical role in this re-evaluation by incorporating cost-effectiveness analysis (CEA) to determine which healthcare interventions provide the most value. CEA can also include equity-weighted analyses that prioritize interventions benefitting disadvantaged populations. CEA compares the costs and outcomes of various strategies, enabling policymakers to allocate resources efficiently, especially in settings with limited healthcare budgets. For example, analyzing cancer screening programs’ cost-effectiveness can identify the most beneficial approach for underserved communities, ensuring that resources are directed where they can achieve the greatest impact.[6]
Furthermore, HEOR’s focus on real-world evidence (RWE) extends beyond controlled clinical trials to understand how treatments perform in everyday practice. This evidence is essential for addressing health disparities, as it reflects the diverse experiences of different patient populations. For instance, RWE during the pandemic showed how vaccine hesitancy and limited access impacted vaccination rates in underserved communities, guiding targeted outreach campaigns. Studies might show that a particular medication is less effective in certain ethnic groups due to genetic variations or disparities in healthcare access, prompting the development of tailored strategies to improve outcomes for these groups.[7]
Patient-reported outcomes (PROs) and electronic PROs (ePROs) are vital components of HEOR that enhance health equity by capturing patients’ perspectives on their health status, quality of life, and treatment satisfaction. Incorporating PROs and ePROs ensures that the voices of all patients, including those from marginalized groups, are considered in healthcare decision-making. This approach helps uncover specific challenges faced by different populations and informs the design of more inclusive and effective interventions.[8]
HEOR also influences policy decisions by providing evidence on the broader social determinants of health, such as education, housing, and employment. Highlighting the impact of these factors on health outcomes allows HEOR to advocate for integrated policies that address these root causes of inequity. For instance, research showing that stable housing reduces emergency room visits has prompted healthcare systems to invest in housing assistance programs. In addition, research might demonstrate that improving access to quality education and stable housing can lead to better health outcomes and reduced healthcare costs, supporting the case for holistic approaches that combine social and health policies.[5]
The pharmaceutical industry benefits significantly from integrating health equity into HEOR. By including diverse populations in clinical trials and subsequent research, companies can develop treatments that are effective across different demographic groups. Failing to include diverse populations can lead to treatments that are less effective or even harmful for certain groups, underscoring the importance of inclusive research practices. This approach not only improves health outcomes but also enhances market access and ensures compliance with regulatory requirements focused on diversity and inclusion.[7]
In conclusion, advancing health equity through HEOR is both a moral imperative and a strategic necessity for optimizing healthcare delivery and outcomes. By embedding equity considerations into economic evaluations, RWE, PROs, and policy research, HEOR can guide the development of more inclusive healthcare strategies. This comprehensive approach ensures that all individuals, irrespective of their background, have access to the care they need to lead healthy and fulfilling lives. Moving forward, it is essential for all healthcare stakeholders to prioritize health equity in their research and decision-making processes, paving the way for a fairer and healthier future for all.
Become A Certified HEOR Professional – Enrol yourself here!
References:
- Health equity. World Health Organisation. Available from: https://www.who.int/health-topics/health-equity#tab=tab_1
- Fautrel B. SP0124 Health economics and health equity: two complementary disciplines.2017;76:31.
- Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. Final Report of the Commission on Social Determinants of Health. World Health Organization; 2008:1 -256. Available from: https://apps.who.int/iris/bitstream/handle/10665/43943/9789241563703_eng.pdf;jsessionid=365271ACE2052888542881700EEDCA8B?sequence=1.
- Burström B, Tao W. Social determinants of health and inequalities in COVID-19. European journal of public health. 2020 Aug 1;30(4):617-8.
- Thomas R, Chalkidou K. Cost–effectiveness analysis. InHealth system efficiency: How to make measurement matter for policy and management. 2016. European Observatory on Health Systems and Policies.
- Fendrick AM, ISPOR. Real-World Evidence: Additional Tool to Support Clinical Decision Making. Available from: https://www.ispor.org/docs/default-source/strategic-initiatives/ispor-rwe-byline-article_10-25-21.pdf?sfvrsn=687e4bc8_0
- Rosenberg SS, Carson BB, Kang A, Lee TH, Pandey R, Rizzo EJ. The Impact of Digital Health Technologies on Health Equity: Designing Research to Capture Patient-Reported Outcomes. ISPOR value & outcomes spotlight. Available from: https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/addressing-assessment-and-access-issues-for-rare-diseases/the-impact-of-digital-health-technologies-on-health-equity-designing-research-to-capture-patient-reported-outcomes.